MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-30-2025
Guardant Health Long-Term Debt 2011-2026 | GH
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Guardant Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.14 B | 1.14 B | 1.14 B | 1.13 B | 806 M | - | - | - | 16.5 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.14 B | 16.5 M | 896 M |
Quarterly Long-Term Debt Guardant Health
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.12 B | 1.12 B | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 1.14 B | - | 1.14 B | 1.13 B | 1.13 B | 1.13 B | 1.13 B | 806 M | 806 M | 806 M | 806 M | - | 33.3 M | 33.3 M | 33.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.14 B | 33.3 M | 943 M |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
15.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Anixa Biosciences
ANIX
|
163 K | $ 3.03 | -2.26 % | $ 98.3 K |  USA |
|
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
2.32 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Brainsway Ltd.
BWAY
|
2.08 M | $ 23.35 | -2.91 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
18.3 M | $ 34.5 | 2.16 % | $ 371 M |  China |
 |
Accelerate Diagnostics
AXDX
|
782 K | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
3.54 M | $ 1.29 | -12.26 % | $ 1.64 M | USA |
 |
Castle Biosciences
CSTL
|
9.74 M | $ 39.74 | 1.48 % | $ 1.1 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
32 K | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
2.15 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
15.5 B | $ 219.29 | -0.08 % | $ 160 B | USA |
 |
Exact Sciences Corporation
EXAS
|
13.2 M | $ 102.41 | 0.1 % | $ 19 B | USA |
 |
Fulgent Genetics
FLGT
|
360 K | $ 26.19 | -0.19 % | $ 792 M | USA |
 |
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
388 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
5.49 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
1.16 B | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
58.6 M | $ 73.31 | -0.93 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
28.3 M | $ 20.55 | -1.23 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
105 M | $ 109.48 | -2.35 % | $ 4.32 B | USA |
 |
DarioHealth Corp.
DRIO
|
24.6 M | $ 10.2 | -0.97 % | $ 289 M | Israel |
 |
Enzo Biochem
ENZ
|
189 K | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
565 M | $ 66.91 | 0.34 % | $ 4.63 B | USA |
 |
Heska Corporation
HSKA
|
307 K | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
546 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
554 M | $ 144.81 | -3.26 % | $ 23 B | USA |
 |
NeoGenomics
NEO
|
340 M | $ 11.99 | -3.35 % | $ 1.52 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.34 B | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
12.8 B | $ 230.33 | -2.19 % | $ 41.8 B | USA |
 |
Charles River Laboratories International
CRL
|
2.24 B | $ 210.51 | -0.59 % | $ 10.8 B | USA |
 |
Personalis
PSNL
|
34.9 M | $ 9.33 | -6.42 % | $ 553 M | USA |
 |
Medpace Holdings
MEDP
|
126 M | $ 582.66 | -1.76 % | $ 18 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.62 B | $ 186.45 | 2.27 % | $ 20.7 B | USA |
|
Biodesix
BDSX
|
40 M | $ 10.11 | 4.66 % | $ 1.31 B | USA |
 |
Motus GI Holdings
MOTS
|
1.24 M | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
106 K | $ 24.07 | -0.78 % | $ 31.2 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
5.33 B | $ 271.34 | 0.56 % | $ 22.8 B | USA |
 |
Mettler-Toledo International
MTD
|
1.83 B | $ 1 370.47 | -1.61 % | $ 29.1 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
3.4 B | $ 181.44 | -2.39 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
450 M | $ 672.84 | -0.57 % | $ 55.5 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
5.7 B | $ 28.66 | -2.02 % | $ 20 B | Niderland |
 |
Agilent Technologies
A
|
2.73 B | $ 133.33 | 0.07 % | $ 40.5 B | USA |
 |
Biomerica
BMRA
|
100 K | $ 2.41 | 0.84 % | $ 5.54 M | USA |